MGD 013

Drug Profile

MGD 013

Alternative Names: Anti-LAG-3 bispecific DART protein; Anti-PD-1; MGD013; PD-1 X LAG-3

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD223 antigen inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Aug 2017 Phase-I clinical trials in Haematological malignancies (Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT03219268)
  • 01 Aug 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT03219268)
  • 03 May 2017 MacroGenics files an IND application for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top